ASSURE: Seladelpar Achieves Clinical Improvement in Primary Biliary Cholangitis

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Related Keywords

,University Of Miami ,Drug Administration ,Schiff Center ,Cynthia Levy ,Digestive Disease Week ,Liver Diseases ,Gamma Glutamyl Transferase ,Alanine Transaminase ,Primary Biliary Cholangitis ,New Therapeutic ,Primary Biliary ,